Please login to the form below

Not currently logged in
Email:
Password:

AZ’s Gabriel Baertschi joins Grünenthal as CEO

He also becomes chairman of the corporate executive board

Grunenthal Gabriel BaertschiAachen, Germany-headquartered Grünenthal has named AstraZeneca's Gabriel Baertschi as its new chief executive officer, with effect from 1 October.

He succeeds Dr Eric-Paul Pâques who was appointed to the role in 2013, and retires at the end of the year.

Baertschi moves to the independent pharmaceutical firm from AstraZeneca, where he currently serves as country president for the company's operations in Japan.

Prior to taking up this role three years ago, Baertschi was AZ's country president for Germany and has led a number of its other operations in emerging markets.

Dr Wilhelm Moll, chairman of Grüenthal's supervisory board, said: “We are delighted that Gabriel Baertschi will join Grüenthal Group as chief executive officer.

“His deep experience in growing the business and developing the organisation in major developed and emerging markets will be a great asset for Grünenthal.

“He joins us at an exciting time when our strategy of expanding our strategic partnerships in research and development in Europe as well as in Latin America are accelerating our global growth.”

Dr Moll added: “We would like to thank Prof Dr Pâques for his outstanding leadership, integrity and extraordinary personal commitment for the future of a successful Grüenthal.”

15th June 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics